QLS5132

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for QLS5132, covering 2025-04-23 to 2026-03-06. Get the full timeline:

Most recent: Clinical Trial Update: QLS5132 Combination Therapy in Advanced Solid Tumors [Phase 1, Phase 2]